首页/数据集/Dataset from Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo

Dataset from Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo

NIAID Data Ecosystem2026-05-10 收录

阿尔茨海默病药物

认知衰退疗效评估

数据链接：

https://doi.org/10.25934/PR00009088 数据链接链接失效反馈

官方服务：

资源简介：

To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.

应用场景：

创建时间：

2026-02-13

阿尔茨海默病药物

局部药物递送

There are many steps involved in the molecular cascade that causes the clinical symptoms of Alzheimer’s disease, and identifying which step to try to block is complex. Recently, a critical step in the

Monash University Figshare2026-02-11 更新80

The transition midpoint temperature (Tm) calculated from DSC curves of Aβ42 in absence and presence of doliroside A.

蛋白质热稳定性分析

阿尔茨海默病药物

The transition midpoint temperature (Tm) calculated from DSC curves of Aβ42 in absence and presence of doliroside A.

Figshare2017-10-31 更新40

Dataset from Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment

阿尔茨海默病药物

前驱期认知功能评估

This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokine

NIAID Data Ecosystem20

Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors

阿尔茨海默病药物

临床试验代表性评估

Objective To determine whether there are differences in age and sex distribution and presence of comorbidities between participants included in randomized controlled trials of acetylcholinesterase inh

NIAID Data Ecosystem80

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease

RIPK1抑制剂开发

阿尔茨海默病药物

Receptor-interacting protein kinase 1 (RIPK1) contributes to a broad set of inflammations and necroptosis in human diseases, which also plays an important role in the pathogenesis of Alzheimer’s disea

NIAID Data Ecosystem40

Dataset from Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo

资源简介：

相关数据集